Black checkmark with a sparkle and a curved line underneath on a white background.
Company

EXAGEN INC.

Ticker
XGN
Sector
Industry
Report date
November 10, 2026
Valye AI Score

91

Very high visibility
Recent developments
Recent developments summary

Recent developments include Q3 2026 financial results showing reduced loss, amendments and drawdowns on the Perceptive Term Loan Facility, and initiation of an at-the-market equity offering program. The company continues research and development on new biomarker assays and maintains active engagement with pharmaceutical partners.

Recent developments:
  • EXAGEN reported a reduction in Q3 2026 loss compared to prior periods, reflecting operational improvements [N1].
  • The company amended its Perceptive Term Loan Facility in late 2026, drawing $5 million of available funds and maintaining up to $30 million in additional borrowing capacity [S2].
  • On November 9, 2026, EXAGEN entered into an at-the-market offering sales agreement with TD Cowen to sell shares of common stock under a 2026 Shelf Registration Statement [S2].
  • Q2 2026 earnings call transcripts and highlights detailed operational turnaround efforts, revenue growth, and gross margin expansion [N4][N5][N6].
  • Research and development efforts continue on Myositis biomarkers with a planned first offering in 2027, Lupus Nephritis biomarkers leveraging Johns Hopkins IP, and AI-driven assays for SLE and RA disease activity [S2].
Overview

EXAGEN INC. is a medical technology company specializing in autoimmune disease diagnostics through its AVISE® portfolio, primarily serving rheumatologists and related specialists. Its flagship product, AVISE® CTD, launched in 2012, aids in differential diagnosis of connective tissue diseases. The company operates a CLIA-certified and CAP-accredited laboratory in California, providing test results typically within five business days. Revenue is derived mainly from AVISE® CTD testing, reimbursed by commercial, government, client payors, and patients. Since late 2022, EXAGEN has undergone an operational turnaround under new leadership, achieving revenue growth and improved margins while reducing expenses and cash burn. The company also pursues partnerships with pharmaceutical companies and contract research organizations for testing services and data use. Research efforts focus on developing new biomarker assays for diseases such as Myositis, Lupus Nephritis, SLE, and RA, with some products in clinical validation or planned launch stages.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. EXAGEN INC. operates a specialized clinical laboratory offering AVISE® branded autoimmune diagnostic tests, primarily AVISE® CTD, which accounted for the majority of revenue in recent periods. The company reported a net loss of $6.3 million and EPS of -$0.25 for Q3 2026, with strong liquidity ratios as of September 30, 2026. Recent amendments to its credit facility and an at-the-market equity offering program reflect ongoing capital management efforts. Research and development focus includes new biomarker assays for autoimmune diseases, with commercial and pharma partnership initiatives ongoing.

Scenarios for XGN

Bull case model:

EXAGEN's focused portfolio of autoimmune diagnostic tests addresses significant unmet clinical needs in rheumatology, supported by a strong foundation of peer-reviewed evidence and specialized sales capabilities. The operational turnaround since 2022 has led to revenue growth and margin expansion, indicating improved execution. Ongoing research and development efforts targeting Myositis, Lupus Nephritis, and disease activity assays for SLE and RA could expand the product offering and deepen clinical utility. Partnerships with pharmaceutical companies and contract research organizations for testing and data use may provide additional revenue streams and market penetration opportunities.

Bear case model:

EXAGEN operates in a niche diagnostic market with inherent challenges including reimbursement variability and reliance on a limited product portfolio, with AVISE® CTD comprising the majority of revenue. The company reported net losses and negative EPS in recent quarters, reflecting ongoing investment and operational costs. Execution risks include successful commercialization of new biomarker assays and sustaining revenue growth amid competitive pressures. Capital raising activities such as amendments to credit facilities and at-the-market offerings may indicate liquidity needs. Regulatory, reimbursement, and market adoption uncertainties pose ongoing risks to financial performance and business model stability.

Moat:

EXAGEN's moat is anchored in its specialized autoimmune diagnostic testing portfolio, particularly the AVISE® CTD test, supported by extensive peer-reviewed clinical validation and proprietary biomarkers. Its CLIA-certified and CAP-accredited laboratory infrastructure and specialized sales force with rheumatology expertise provide differentiated customer engagement and service. Intellectual property licenses, such as those from Johns Hopkins University for Lupus Nephritis biomarkers, and ongoing research collaborations with pharmaceutical companies further strengthen its competitive position. The company's focus on complex autoimmune diseases and tailored diagnostic solutions creates barriers to entry for competitors lacking similar clinical validation and specialized expertise.

Risks overview
Risks summary
The biggest risk for EXAGEN INC. is operational execution related to product development and commercialization amid reimbursement variability and capital requirements.
Risks details:

• Reimbursement and Coverage Risks: Variability in reimbursement rates from commercial, government, and client payors can impact revenue and profitability.
• Product Concentration Risk: Heavy reliance on AVISE® CTD for revenue exposes the company to risks if demand or reimbursement for this product declines.
• Operational Execution Risk: Successful development, validation, and commercialization of new biomarker assays are critical to growth and diversification.
• Liquidity and Capital Access Risk: The company’s use of credit facilities and equity offerings indicates ongoing capital needs, which may affect financial flexibility.
• Regulatory and Market Adoption Risk: Changes in regulatory requirements or slower adoption of diagnostic tests by clinicians could adversely affect business performance.

FINAL FORECAST FOR XGN

Final take one line
EXAGEN INC. demonstrates very high visibility through detailed SEC filings and extensive recent news, highlighting its specialized autoimmune diagnostic business, operational turnaround, and ongoing R&D efforts.
Final take 12 to 24 month view

Business trends: Continued focus on autoimmune diagnostic testing with expansion into new biomarker assays and partnerships with pharmaceutical companies.
Execution milestones: Operational turnaround with revenue growth and margin expansion; amendments and drawdowns on credit facilities; launch of new biomarker products in development.
Key risks: Reimbursement variability, product concentration, execution on new product commercialization, liquidity needs, and regulatory adoption uncertainties.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

91
LLM visibility overview
LLM Visibility known facts
  • EXAGEN INC. is a medical technology company focused on the design, development, and commercialization of innovative testing products under the AVISE® brand for differential diagnosis, prognosis, and monitoring of complex rheumatic, autoimmune, and autoimmune-related diseases such as SLE and RA.
  • The flagship product, AVISE® CTD, launched commercially in 2012, enables differential diagnosis for connective tissue diseases and related diseases with overlapping symptoms, addressing limitations of traditional screening methods.
  • Revenue from AVISE® CTD comprised approximately 90% of total revenue for the nine months ended September 30, 2026 and 89% for the same period in 2025.
  • The company operates a CLIA-certified and CAP-accredited clinical laboratory in Vista, California, performing all AVISE® tests with typical reporting within five business days.
  • Reimbursement for testing services comes from commercial payors, government payors, client payors, and patients, with rates varying by product and payor.
  • Since late 2022, EXAGEN has undergone an operational turnaround under CEO John Aballi, resulting in revenue growth, gross margin expansion, and reduced operating expenses and cash burn.
  • EXAGEN has a specialized sales force covering 45 U.S. territories, with personnel trained to interpret test results and engage rheumatologists in tailored discussions.
  • The company is leveraging its clinical laboratory to enter agreements with pharmaceutical companies and contract research organizations for use of testing products and de-identified data.
  • Research and development efforts include advancing Myositis biomarkers with a planned first offering in 2027, Lupus Nephritis biomarkers leveraging Johns Hopkins IP, and development of SLE and RA disease activity assays using AI and protein antibody markers.
  • As of September 30, 2026, EXAGEN reported cash and cash equivalents of $28.1 million, current assets of $45.3 million, current liabilities of $13.1 million, a current ratio of 3.46, and a cash ratio of 2.14.
  • The company reported a net loss of $6.3 million and basic and diluted EPS of -$0.25 for the quarter ended September 30, 2026.
  • EXAGEN amended its Perceptive Term Loan Facility in late 2026, drawing $5 million of the available $35 million tranche, with the facility maturing April 25, 2030, secured by a first lien on substantially all assets.
  • On November 9, 2026, EXAGEN entered an at-the-market offering sales agreement with TD Cowen to sell shares of common stock from time to time under a 2026 Shelf Registration Statement.
  • Recent news highlights include Q3 loss reduction reported on November 10, 2026, and multiple earnings call transcripts and reports for Q1 and Q2 2026, reflecting ongoing operational updates and financial results.
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
  • N4
  • N5
  • N6
  • N7
  • N8
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-10 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | Exagen Inc Q3 Loss Drops | https://www.nasdaq.com/articles/exagen-inc-q3-loss-drops
  • N2 | 2026-11-06 | www.nasdaq.com | Nephros Inc. (NEPH) Tops Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/nephros-inc-neph-tops-q3-earnings-and-revenue-estimates
  • N3 | 2026-11-04 | www.nasdaq.com | Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates | https://www.nasdaq.com/articles/zimmer-biomet-zbh-q3-earnings-and-revenues-beat-estimates
  • N4 | 2026-08-11 | www.nasdaq.com | Exagen (XGN) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/exagen-xgn-q2-2026-earnings-call-transcript
  • N5 | 2026-08-04 | www.nasdaq.com | Exagen Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/exagen-q2-earnings-call-highlights
  • N6 | 2026-08-04 | www.nasdaq.com | Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/exagen-inc-xgn-reports-q2-loss-beats-revenue-estimates
  • N7 | 2026-05-12 | www.nasdaq.com | Exagen (XGN) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/exagen-xgn-q1-2026-earnings-transcript
  • N8 | 2026-05-11 | www.nasdaq.com | Exagen Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/exagen-q1-earnings-call-highlights
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine